In this article, we will take a detailed look at the top 10 stocks insiders are selling in March. We previously covered the top 10 stocks insiders are buying in March.

Wall Street experienced a challenging week, marked by turbulence as the broader market entered a correction, declining 10.1% from its record high in February. All three major indexes dropped between 2.3% and 3.1% over the week. However, Friday brought a little more optimism among investors as all three major indexes closed a bit higher. Blue-chip stocks closed 1.65% higher, the broader market index gained 2.13% and the NASDAQ Composite closed Friday session 2.61% higher.

This week continues to keep investors on their toes as the U.S. retail sales report, scheduled for release on Monday, will provide insights into consumer spending. According to Yahoo Finance, some experts believe investors will closely examine the report for signs of an economic slowdown. Experts polled by Dow Jones expect retail sales to have increased by 0.6% last month.

Investors are also closely watching for another significant update this week: the Federal Reserve’s decision on interest rates. Since September, the Fed has cut interest rates three times and still, the broader market entered a correction.

Examining recent insider trades can offer valuable insights, as executives often have a deeper understanding of their companies. For instance, when a CEO or CFO buys company stock, it may signal strong confidence in the business’s future.

However, insider selling doesn’t necessarily reflect a lack of confidence; it could be due to personal financial needs or a desire to diversify investments. These transactions are often executed through pre-arranged plans, like 10b5-1 plans, to avoid any appearance of improper timing. While insider activity can be informative, it’s important to consider it alongside the company’s financial health, market trends, and industry developments.

Our Methodology

To identify the 10 stocks insiders are selling in March we used Insider Monkey’s insider trading stock screener and looked for stocks where at least three insiders sold shares this month. With each stock, we note the number of insiders who recently sold shares and the company’s market capitalization.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Let’s take a look at the 10 stocks insiders are selling in March.

10. Equinix, Inc. (NASDAQ:EQIX)

Number of Insiders Selling: 8

Market Capitalization: $81.53 billion

We start this list with one of the world’s largest third-party data center providers, Equinix. The Redwood City, California-based company focuses exclusively on data center operations, offering colocation, interconnection, and internet connectivity services through a neutral platform that enables seamless data exchange between networks. Equinix operates 268 data centers across 34 countries, spanning 33.7 million gross square feet on every major continent.

For the full year of 2024, the company reported revenues of $8.75 billion, up by 7% from the previous year. Net income attributable to common stockholders amounted to $815 million, down 16% year-over-year. Adjusted EBITDA was $4.1 billion, representing a 160 basis-point year-over-year improvement.

In March, eight insiders, including the company’s CEO, sold a total of $5.39 million worth of Equinix shares at an average price of $860.15 per share. Currently, the stock trades at $837.68 per share, having lost 11.16% year-to-date and 2.67% over the past 12 months.

Nineteen analysts have given an average “Buy” rating on Equinix stock with a price target of $971.56 per share, according to StockAnalysis.

Equinix is also among the 20 best data center stocks to buy according to billionaires.

9. Casella Waste Systems, Inc. (NASDAQ:CWST)

Number of Insiders Selling: 8

Market Capitalization: $6.81 billion

Next, among the stocks insiders are saying goodbye to in March, is a vertically integrated solid waste services company, Casella Waste Systems. The Rutland, Vermont-based company’s services include waste collection, recycling, disposal, and transfer operations, catering to various residential, commercial, and industrial customers. The company also markets recyclable materials such as cardboard, plastics, and metals.

Mad Money host Jim Cramer recently talked about the stock and said, “You know this one has been around forever and it just caught fire. I think it’s good but you know what? I am gonna go back to WM. I think WM is terrific and it just had a dip and it’s a little bit cheaper.”

In March, eight insiders, including the company’s CEO, sold a total of approximately $4.37 million worth of Casella shares at an average price of $107.60 per share. The stock rose 1.60% year-to-date, and is now trading at $107.50. Over the past 12 months, Casella returned 11.45% to its investors.

Based on five analysts’ estimates, Casella stock is a “Moderate Buy” with a price target of $117.75, according to MarketBeat.

8. CNH Industrial N.V. (NYSE:CNH)

Number of Insiders Selling: 9

Market Capitalization: $16.14 billion

CNH Industrial is a global equipment and services company specializing in the design, production, and sale of agricultural and construction equipment. The Basildon, United Kingdom-based company operates across North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers farm machinery and implements under brands like Case IH, New Holland, STEYR, and Raven, including tractors, harvesters, and precision agriculture solutions.

Its construction segment produces equipment such as excavators, dozers, graders, and loaders under CASE Construction Equipment, New Holland Construction, and Eurocomach brands. Its Financial Services segment, branded as Banco CNH, provides financing for customers and dealers, including loans for new and used equipment, charge accounts, and wholesale financing.

For the full year of 2024, CNH disclosed revenue of $19.84 billion, down 20% year-over-year. Net income amounted to $1.26 billion, compared to net income of $2.29 billion in the prior year. The company reduced its agricultural production hours by 34% in the fourth quarter of 2024, and 28% for the whole year, improving efficiency, to counter the declining demand. These advances helped lower stock levels by over $700 million at the dealer’s end in the fourth quarter. Through manufacturing process optimization and increasing operational efficiency, the company was able to achieve $600 million in cost savings.

In March, nine insiders, including the company’s CEO, and CFO, sold a total of approximately $4.79 million worth of CNH Industrial shares at an average price of $11.64 per share. Currently, the stock trades at $12.93 per share, having gained 12.12% year-to-date, and 4.61% over the past 12 months.

The consensus rating on CNH Industrial stock from 12 analysts is “Moderate Buy” with a price target of $15.38, according to MarketBeat.

7. Waste Management, Inc. (NYSE:WM)

Number of Insiders Selling: 10

Market Capitalization: $90.42 billion

The seventh stock, among 10 insiders are dropping in March is an industrial company providing waste management solutions, Waste Management. Based in Houston, Texas, the company provides collection services, including picking up and transporting waste and recyclable materials to a transfer station. Its network counts 337 transfer stations, 254 active landfill disposal sites, 97 recycling plants and six independent power production plants. Waste Management serves nearly 21 million customers across the U.S., Canada, Mexico, and Puerto Rico.

For the full year 2024, the company reported revenue of $22.06 billion, slightly down from $22.43 billion in 2023. Jim Fish, Waste Management’s President and CEO, stated that the company anticipates “a second consecutive year of double-digit growth in adjusted operating EBITDA in 2025.” Additionally, Waste Management’s Board of Directors recently announced a quarterly cash dividend of $0.825 per share.

The stock is also among the 10 best stocks to buy according to Bill Gates.

In March, 10 insiders, including the company’s COO, sold a total of $6.87 million worth of Waste Management’s shares at a price of $230.74 per share. Year-to-date, the stock gained 11.43% and is now trading at $224.86 per share. Over the past 12 months, Waste Management returned 6.23% to its investors.

StockAnalysis reports that 20 analysts have given a “Buy” rating on Waste Management stock with a price target of $235.44.

6. Samsara Inc. (NYSE:IOT)

Number of Insiders Selling: 10

Market Capitalization: $21.36 billion

Samsara is a provider of Internet of Things (IoT) solutions. The San Francisco, California-headquartered company provides internet-connected sensor hardware and software solutions for industrial IoT applications and fleet management. Its Connected Operations Cloud enables organizations to integrate and analyze IoT data to advance operational efficiency, safety, and sustainability.

For the fiscal 2025, the company reported revenue of $1.25 billion, compared to $937.39 million in fiscal 2024. Net loss amounted to $154.91 million, compared to net loss of $286.73 million in the same period of the prior year.

Recently, the company announced CTC Manager, a new solution certified by the California Air Resources Board (CARB) to streamline emissions compliance for fleets navigating the state’s regulatory requirements. CTC Manager allows organizations to remotely collect emissions data and automate reporting processes, reducing downtime, administrative overhead, and expenses.

In March, 10 insiders, including the company’s CEO, sold a total of $56.82 million worth of Samsara shares at an average price of $38.46 per share. Currently, the stock trades at $38.06 per share, having declined 12.89% since the beginning of the year. Over the past 12 months, the company shares gained 3%.

According to 14 analysts’ estimates, Samsara is a “Moderate Buy” with an average price target of $51.67, writes TipRanks.

5. First Solar, Inc. (NASDAQ:FSLR)

Number of Insiders Selling: 10

Market Capitalization: $14.19 billion

In the middle of this list of 10 stocks insiders are selling in March, is solar technology company, First Solar. The Tempe, Arizona-based company provides photovoltaic (PV) solar energy solutions globally, including the U.S., France, India, and Chile. It produces and sells thin-film cadmium telluride (CdTe) solar modules, offering a lower-carbon alternative to traditional crystalline silicon panels by converting sunlight into electricity.

For the full year 2024, First Solar disclosed net sales of $4.21 billion, which compares to $3.32 billion in 2023. Net income amounted to $1.29 billion, compared to $830.77 million in the previous year. For 2025, the company projects revenue in the range of $5.3 to $5.8 billion.

“In 2024, we continued building the foundations required for our long-term growth strategy,” stated Mark Widmar, chief executive officer, First Solar. “Even as we maintained a highly selective approach to bookings, we expanded manufacturing capacity by commissioning our Alabama facility and progressed construction of our new Louisiana facility, established the infrastructure we anticipate will accelerate innovation with a new R&D center in Ohio, and produced and shipped a historic volume of modules.”

In March, 10 insiders, including the company’s CEO, and CSO, sold a total of $474,002 worth of First Solar shares at an average price of $132.96 per share. Since the beginning of the year, the stock declined 24.81% and currently trades at $132.51. Over the past 12 months, First Solar shares dropped 11.35%.

The consensus rating from 24 Wall Street analysts on First Solar stock is “Strong Buy” with a price target of $252.52. The average price target suggests a 90.57% upside from the latest price.

First Solar is also among the 13 most undervalued NASDAQ stocks to buy according to hedge funds.

4. Altair Engineering Inc. (NASDAQ:ALTR)

Number of Insiders Selling: 10

Market Capitalization: $9.55 billion

Altair Engineering provides software and cloud solutions for simulation, high-performance computing, data analytics, and AI, serving clients in the U.S. and globally. The Troy, Michigan-based company operates in two segments: Software, and Client Engineering Services.

In January, the company announced that its stockholders had approved the proposed merger agreement with Siemens Industry Software Inc., a subsidiary of Siemens AG. Under the agreement, Siemens will buy all the outstanding shares of Altair’s common stock for $113.00 per share in cash.

Upon completion of the transaction, Altair’s securities will no longer be listed on any public stock exchange.

For the full 2024, the company disclosed a total revenue of $665.8 million compared to $612.7 million in 2023, an increase of 8.7% in reported currency and 9.8% in constant currency. Net income amounted to $14.2 million, which compares to a net loss of $8.9 million in 2023. Adjusted EBITDA was $149.9 million, which compares to $129.1 million in the prior year. Free cash flow was $140.0 million, compared to $117.1 million for the full year of 2023.

In March, 10 insiders, including the company’s COO, and CFO, sold a total of around $334,850 worth of Altair Engineering shares at an average price of $111.41 per share. The stock gained 2.05% since the beginning of the year and is now trading at $111.35. Over the last 12 months, it returned 38.70%.

According to data from StockAnalysis, seven analysts have an average “Hold” rating on the Altair Engineering stock with a price target of $101.0. The average price target indicates a decrease of 9.30% from the latest price.

3. Adaptive Biotechnologies Corporation (NASDAQ:ADPT)

Number of Insiders Selling: 10

Market Capitalization: $1.08 billion

The third among the 10 stocks insiders are getting rid of in March is a commercial-stage biotech, Adaptive Biotechnologies. The Seattle, Washington-based company is focused on the development of an immune medicine platform for the diagnosis and treatment of various diseases.

Recently, the company announced it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity.

The Centers for Medicare Centers for Medicare & Medicaid Services recently set a favorable reimbursement rate of $2,007 for the company’s clonoSEQ test.

Revenue for the fourth quarter and full year 2024 was $47.5 million and $179.0 million, respectively. The MRD business, which contributed 85% of revenue in the fourth quarter and 81% of revenue in the full year, grew 31% and 42% over the corresponding periods a year ago. Net loss was $159.6 million in 2024, compared to $225.3 million in 2023. Adjusted EBITDA (non-GAAP) was a loss of $80.4 million for 2024, compared to a loss of $116.4 million in the prior year. Cash, cash equivalents and marketable securities were $256.0 million as of December 31, 2024.

In March, 10 insiders, including the company’s CEO, COO, and CFO sold a total of close to $4 million worth of Adaptive Biotechnologies shares at an average price of $7.11 per share. The stock gained 21.33% since the beginning of the year, and is currently trading at $7.28. Over the past 12 months, Adaptive Biotechnologies shares returned 21.33% to its investors.

Five analysts have given a “Moderate Buy” rating to Adaptive Biotechnologies stock with an average price target of $9.10, according to MarketBeat.

2. Skyward Specialty Insurance Group, Inc. (NASDAQ:SKWD)

Number of Insiders Selling: 11

Market Capitalization: $1.99 billion

Skyward Specialty is an insurer with a focus on niche markets, providing tailored underwriting solutions for risk that traditional insurers often avoid. Skyward operates in two segments – admitted insurance, which includes state-regulated policies, and non-admitted insurance, which provides pricing flexibility and coverage for specialized risks. The stock was also among the 10 top insider stock buys and sells in January.

Previously we discussed a bull case theory for Skyward, which suggests that even though natural disasters provide short-term risks, the company’s disciplined pricing and risk management should protect its capital in the longer run. In 2023, many property and casualty insurers posted underwriting losses with a combined ratio of 101.5%, Skyward delivered a 90.7% ratio, showcasing its capability to drive consistent profits.

In March, 11 insiders sold a total of approximately $2.88 million worth of Skyward shares at an average price of $50.34 per share. Year-to-date, the stock declined 1.50% and is now trading at $49.78. However, over the past 12 months, Skyward shares rose 37.02%.

For the full year of 2025, the company disclosed net income of $80.69 million, compared to $40.42 million in 2024. For 2025, the company projects a net income of between $138.0 million and $150.0 million, and a combined ratio between 91% and 92%, inclusive of 2.0 to 2.5 points of catastrophe losses.

According to nine analysts’ estimates, Skyward is a “Strong Buy” with a price target of $57.86, writes TipRanks.

1. Blueprint Medicines Corporation (NASDAQ:BPMC)

Number of Insiders Selling: 11

Market Capitalization: $5.73 billion

First among the 10 stocks insiders are selling this month is the biopharmaceutical company Blueprint Medicines. The Cambridge, Massachusetts-headquartered company is focused on developing targeted treatments for cancers and blood disorders. Its main revenue stream is AYVAKIT (avapritinib), a treatment for systemic mastocytosis (SM) and gastrointestinal stromal tumors.

Additionally, Blueprint Medicines is working on BLU-263, a potent, orally available KIT inhibitor designed to treat indolent SM and other mast cell disorders. The company is also developing GAVRETO for patients with RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma.

For the full year of 2024, the company reported revenues of $508.8 million, including $479.0 million in net product revenues from sales of AYVAKIT and $29.9 million in collaboration and license revenues. Blueprint Medicines recorded $72.0 million and $249.4 million in revenues in the fourth quarter and year ended Dec. 21, 2023, respectively. Net loss for the year 2024 was $67.1 million, compared to a net loss of $507.0 million in 2023. As of Dec. 31, 2024, cash, cash equivalents and investments were $863.9 million, as compared to $767.2 million as of Dec. 31, 2023.

The company projects 2025 revenue of $680 million to $710 million suggesting AYVAKIT is on track to achieve $2 billion in revenue by 2030.

In March, 11 insiders, including the company’s CEO, CSO, and CFO, sold a total of around $6.69 million worth of Blueprint Medicines shares at an average price of $89.50 per share. Currently, the stock trades at $89.58 per share, having gained 2.71% year-to-date, and 3.18% over the past 12 months.

According to StockAnalysis, the consensus rating for Blueprint Medicines stock from 20 analysts is “Buy.” The average price target is $125.0, suggesting an upside of 39.54%.

Blueprint Medicines is also among the 10 oversold biotech stocks to buy now.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.